Finance ❯ Investments ❯ Stock Market ❯ Securities

Investor Rights

Corcept Investors Face April 21 Deadline to Seek Lead Role in Securities Class Action

Filings claim the company downplayed FDA objections to relacorilant by touting its approval prospects.

Corcept Faces Securities Class Action Over Relacorilant Disclosures as Firms Rally Investors Before April 21 Deadline

Vistagen Investors Urged to Seek Lead Plaintiff Role in Securities Suit as March 16 Deadline Nears

Gauzy Investors Face Feb. 6 Lead‑Plaintiff Deadline in Securities Class Action

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Baxter Investors Urged to Act as Dec. 15 Lead-Plaintiff Deadline Nears in Novum Pump Lawsuits

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

Law Firms Press Synopsys Investors Ahead of Dec. 30 Lead‑Plaintiff Deadline

MoonLake Faces Expanding Securities Suits as Lead-Plaintiff Deadline Nears

Primo Brands Faces Investor Suits Over BlueTriton Integration as Firms Seek Lead Plaintiffs

James Hardie Investors Face Dec. 23 Deadline in U.S. Securities Suit Over Alleged Inventory Misstatements

CarMax Investor Suits Escalate as Amended Filings Extend Class Period to Nov. 5

Primo Brands Investors Pressed to Act as Securities Suits Target BlueTriton Merger Disclosures

Stride Investor Litigation Widens With New Class Action and Fresh Probes

Stride Investors Urged to Seek Lead Role in Securities Case Before January 12

Stride Faces Federal Securities Class Action Over Enrollment and Compliance Allegations

MoonLake Investors Courted by Law Firms as Lead‑Plaintiff Deadline Nears in SDNY Securities Case

Freeport Faces Investor Class Action Over Grasberg Safety Disclosures as Firms Court Lead Plaintiff

Synopsys Investors Face Dec. 30 Deadline to Seek Lead Role in Securities Class Action Over Design IP Disclosures

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures